Play
A ‘next generation’ vaccine for malaria has shown success in its first human trial. The phase 1 study saw a strong immune response in 10 healthy volunteers. The vaccine was created by genetically engineering the malaria parasite to make it weaker. Scientist removed the three genes needed for it to successfully infect and cause disease in humans. None of the participants developed malaria symptoms, and showed a strong protective antibody response.
Jan 5, 2017
Play
Fat Cat Wednesday is a day where FTSE 100 bosses will have already earned more than the average worker in the UK makes all year.
Jan 4, 2017
Jubilant Life Sciences wins US business orders; IT services firm Ramco Systems's Malaysian arm bags a big project from Panasonic
Jan 4, 2017
Tata Sons served a notice to Mistry on Tuesday informing him about the company's intention.
Jan 4, 2017
Play
Play
